Aprea Therapeutics (APRE) Prepaid Assets (2018 - 2026)
Aprea Therapeutics (APRE) posted quarterly Prepaid Assets of $779238.0 for Q1 2026, up 39.48% year-over-year from $558689.0 in Q1 2025, and down 18.99% quarter-over-quarter from $961899.0 in Q4 2025.
Aprea Therapeutics (APRE) Prepaid Assets (2018 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Prepaid Assets for 9 consecutive years, with $779238.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets rose 39.48% year-over-year to $779238.0; the TTM figure through Mar 2026 stood at $779238.0 (up 39.48% YoY), while the FY2025 annual figure was $961899.0, up 32.45% from the prior year.
- Prepaid Assets fell to $779238.0 in Q1 2026 per APRE's latest filing, from $961899.0 in the prior quarter.
- Across five years, Prepaid Assets topped out at $2.4 million in Q1 2022 and bottomed at $225936.0 in Q3 2025.
- Historically, Prepaid Assets has averaged $832009.4 across 5 years, with a median of $779238.0 in 2026.
- Annual changes were most pronounced in 2022 — Prepaid Assets sank 61.04% — and 2026, when it jumped 39.48%.
- Aprea Therapeutics' Prepaid Assets stood at $1.4 million in 2022, then slumped by 33.11% to $914275.0 in 2023, then dropped by 20.57% to $726254.0 in 2024, then soared by 32.45% to $961899.0 in 2025, then slipped by 18.99% to $779238.0 in 2026.
- Business Quant data shows APRE's Prepaid Assets at $779238.0 in Q1 2026, $961899.0 in Q4 2025, and $225936.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aprea Therapeutics | 34.25 Mn | 34.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 679,686.00 |
| Mar 31, 2026 | 779,238.00 |
| Dec 31, 2025 | 961,899.00 |
| Sep 30, 2025 | 225,936.00 |
| Jun 30, 2025 | 395,011.00 |
| Mar 31, 2025 | 558,689.00 |
| Dec 31, 2024 | 726,254.00 |
| Sep 30, 2024 | 234,195.00 |
| Jun 30, 2024 | 865,092.00 |
| Mar 31, 2024 | 698,864.00 |
| Dec 31, 2023 | 914,275.00 |
| Sep 30, 2023 | 286,263.00 |
| Jun 30, 2023 | 953,670.00 |
| Mar 31, 2023 | 1.02 Mn |
| Dec 31, 2022 | 1.37 Mn |
| Sep 30, 2022 | 361,178.00 |
| Jun 30, 2022 | 1.40 Mn |
| Mar 31, 2022 | 2.39 Mn |
| Dec 31, 2021 | 3.51 Mn |
| Sep 30, 2021 | 750,929.00 |